Cary, N.C. , August 7, 2025 – Effective June 15, VIJOICE® (alpelisib) is now exclusively available at Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas. VIJOICE® (alpelisib) is a kinase inhibitor indicated for the treatment of adult and pediatric patients 2 years of age and older with severe manifestations of PIK3CA-Related Overgrowth Spectrum (PROS) who require systemic therapy.
PROS is a group of rare genetic disorders caused by mutations in the PIK3CA gene, which plays a key role in producing a protein that helps regulate cell growth, division and survival. These mutations may lead to abnormal overgrowth of various tissues such as fat, muscle, bone, nerve, brain and blood vessels.
“Biologics is honored to have been selected as the exclusive specialty pharmacy for VIJOICE,” says Ela Lourido, vice president and general manager, Biologics by McKesson. “This network change reflects the trust placed in our team to deliver high-touch, personalized care to those facing complex, life-altering conditions. For individuals living with PROS, access to this specialized therapy can meaningfully improve quality of life. Behind every prescription is a story of courage, and we’re proud to stand beside these individuals and their families with compassion, expertise, and unwavering support.”
Biologics by McKesson is committed to and recognized for its level of customer service as well as its innovative, high-touch, and multidisciplinary approach. Putting patients first in all they do, the Biologics’ pharmacy team includes pharmacists with in-depth knowledge of therapies, experienced nurses, and financial counselors who are familiar with various financial assistance programs and organizations that help patients.
For more information about VIJOICE®, please visit vijoice.com.